Novavax: Difference between revisions
Content deleted Content added
January2009 (talk | contribs) add BARDA contract |
January2009 (talk | contribs) add adjuvant information |
||
| Line 41: | Line 41: | ||
Products in its pipeline include vaccines for rabies, pandemic influenza (including H1N1, SARS and MERS), seasonal influenza, and respiratory syncytial virus (RSV).<ref>{{cite web|url=http://www.novavax.com/go.cfm?do=Page.View&pid=13|title=Clinical Stage Pipeline|website=novavax.com|accessdate=30Apr2014}}</ref> |
Products in its pipeline include vaccines for rabies, pandemic influenza (including H1N1, SARS and MERS), seasonal influenza, and respiratory syncytial virus (RSV).<ref>{{cite web|url=http://www.novavax.com/go.cfm?do=Page.View&pid=13|title=Clinical Stage Pipeline|website=novavax.com|accessdate=30Apr2014}}</ref> |
||
The company |
The company has run 14 clinical trials as of 30Apr2014.<ref>{{cite web|url=http://www.novavax.com/go.cfm?do=Page.View&pid=81|title=Clinical Trials|website=novavax.com|accessdate=30Apr2014}}</ref> 11 trials are completed.<ref>{{cite web|url=http://www.clinicaltrials.gov/ct2/results?term=novavax&Search=Search|title=Novavax Clinical trials|website=clinicaltrials.gov|accessdate=03May2014}}</ref> The company announced preliminary posistive safety and immunogenicity data for its RSV vaccine candidate in its Phase 2 clinical trial in women of childbearing age.<ref>{{cite web|url=http://markets.on.nytimes.com/research/stocks/news/press_release.asp?docTag=201404281613PRIMZONEFULLFEED10078667&feedID=600&press_symbol=218607|title=Novavax Announces Positive Top-Line Data from Dose-Confirmatory Phase 2 Clinical Trial of its RSV Vaccine Candidate in Women of Childbearing Age|website=NYtimes.com|date=28Apr2014|accessdate=03May2014}}</ref> |
||
In 2011, Novavax was awarded a $97 million contract with the [[Biomedical Advanced Research and Development Authority]] (BARDA) to develop influenza vaccines.<ref>{{cite web|url=https://www.fbo.gov/index?s=opportunity&mode=form&id=80ccb0ca1485db6502584999e4e5e0e7&tab=core&_cview=1|title=Advanced Development of Recombinant Influenza Vaccine Products and Manufacturing Capabilities for Pandemic Preparedness|website=FedBizOpps.gov|accessdate=03May2014}}</ref> |
In 2011, Novavax was awarded a $97 million contract with the [[Biomedical Advanced Research and Development Authority]] (BARDA) to develop influenza vaccines.<ref>{{cite web|url=https://www.fbo.gov/index?s=opportunity&mode=form&id=80ccb0ca1485db6502584999e4e5e0e7&tab=core&_cview=1|title=Advanced Development of Recombinant Influenza Vaccine Products and Manufacturing Capabilities for Pandemic Preparedness|website=FedBizOpps.gov|accessdate=03May2014}}</ref> |
||
| Line 49: | Line 49: | ||
The company is running clinical trials for adjuvants, with applications for avian flu, seasonal flu, malaria, HIV, HSV-2 therapeutic and prophylactic, Chlamydia, Gonnorrhea, and rabies. Some projects are in partnership with [[Johnson & Johnson]], [[Crucell]], Genocea Biosciences, and the [[Edward Jenner Institute for Vaccine Research|Jenner Institute]]. <ref>{{cite web|url=http://www.novavax.com/go.cfm?do=Page.View&pid=172|title=Adjuvant Pipeline|website=novavax.com|accessdate=30Apr2014}}</ref> |
The company is running clinical trials for adjuvants, with applications for avian flu, seasonal flu, malaria, HIV, HSV-2 therapeutic and prophylactic, Chlamydia, Gonnorrhea, and rabies. Some projects are in partnership with [[Johnson & Johnson]], [[Crucell]], Genocea Biosciences, and the [[Edward Jenner Institute for Vaccine Research|Jenner Institute]]. <ref>{{cite web|url=http://www.novavax.com/go.cfm?do=Page.View&pid=172|title=Adjuvant Pipeline|website=novavax.com|accessdate=30Apr2014}}</ref> |
||
It acquired the Abisco-100 Adjuvant technology with the purchase of Swedish company Isconova AB. The adjuvant is comprised of [[saponin]]s, [[cholesterol]], and dimyristoyl [[phosphatidylcholine]] (DPCC).<ref>{{cite web|url=http://www.thermoscientific.com/content/dam/tfs/ATG/CMD/CMD%20Documents/AN-1082-Analysis-Multicomponent-Vaccine-Adjuvants-AN70886-E.pdf|title=Direct Analysis of Multicomponent |
|||
Vaccine Adjuvants by HPLC with |
|||
Charged Aerosol Detection|last=Thomas|first=Dave|website=thermoscientific.com|accessdate=03May2014}}</ref> |
|||
Its Matrix-M adjuvant is comprised of 40 nm nanoparticles with saponins, cholesterol and phospholipid.<ref>{{cite journal|url=http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0041451|title=Matrix-M™ Adjuvant Induces Local Recruitment, Activation and Maturation of Central Immune Cells in Absence of Antigen|last=Reimer|first=Jenny M.|last2=Karlsson|first2=Karin H.|last3=Lövgren-Bengtsson| first3=Karin|last4=Magnusson|first4=Sofia E.|last5=Fuentes|first5=Alexis|last6=Stertman|first6=Linda|DOI= 10.1371/journal.pone.0041451|date= 23 Jul 2012|journal=PLOSone|accessdate=03May2014}}</ref> |
|||
==See also== |
==See also== |
||
Revision as of 00:55, 4 May 2014
An editor has nominated this article for deletion. You are welcome to participate in the deletion discussion, which will decide whether or not to retain it. |
 | The topic of this article may not meet Wikipedia's notability guidelines for companies and organizations. (April 2014) |
 | This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. (April 2014) |
 | |
| Company type | Public |
|---|---|
| NYSE: NVAX S&P 500 Component | |
| Industry | biotechnology |
| Founded | (1987) |
| Headquarters | , |
Area served | Worldwide |
| Products | vaccines |
| Revenue | 22,076,000 (2012) |
| Total assets | 102,345,000 (2012) |
Number of employees | 213 (2014) |
| Website | www |
Novavax, Inc. is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, which specializes in creating recombinant protein nanoparticle vaccines to address a broad range of infectious diseases.[1]
The company has recombinant vaccine design and manufacturing technology and adjuvant technology.
Pipeline
Products in its pipeline include vaccines for rabies, pandemic influenza (including H1N1, SARS and MERS), seasonal influenza, and respiratory syncytial virus (RSV).[2]
The company has run 14 clinical trials as of 30Apr2014.[3] 11 trials are completed.[4] The company announced preliminary posistive safety and immunogenicity data for its RSV vaccine candidate in its Phase 2 clinical trial in women of childbearing age.[5]
In 2011, Novavax was awarded a $97 million contract with the Biomedical Advanced Research and Development Authority (BARDA) to develop influenza vaccines.[6]
Adjuvants
The company is running clinical trials for adjuvants, with applications for avian flu, seasonal flu, malaria, HIV, HSV-2 therapeutic and prophylactic, Chlamydia, Gonnorrhea, and rabies. Some projects are in partnership with Johnson & Johnson, Crucell, Genocea Biosciences, and the Jenner Institute. [7]
It acquired the Abisco-100 Adjuvant technology with the purchase of Swedish company Isconova AB. The adjuvant is comprised of saponins, cholesterol, and dimyristoyl phosphatidylcholine (DPCC).[8] Its Matrix-M adjuvant is comprised of 40 nm nanoparticles with saponins, cholesterol and phospholipid.[9]
See also
- H5N1 clinical trials
- Influenza A virus subtype H7N9
- John Otho Marsh, Jr.
- Middle East respiratory syndrome
- Curt Weldon
- NASDAQ Biotechnology Index
References
- ^ "About Us". novavax.com. Retrieved 30Apr2014.
{{cite web}}: Check date values in:|accessdate=(help) - ^ "Clinical Stage Pipeline". novavax.com. Retrieved 30Apr2014.
{{cite web}}: Check date values in:|accessdate=(help) - ^ "Clinical Trials". novavax.com. Retrieved 30Apr2014.
{{cite web}}: Check date values in:|accessdate=(help) - ^ "Novavax Clinical trials". clinicaltrials.gov. Retrieved 03May2014.
{{cite web}}: Check date values in:|accessdate=(help) - ^ "Novavax Announces Positive Top-Line Data from Dose-Confirmatory Phase 2 Clinical Trial of its RSV Vaccine Candidate in Women of Childbearing Age". NYtimes.com. 28Apr2014. Retrieved 03May2014.
{{cite web}}: Check date values in:|accessdate=and|date=(help) - ^ "Advanced Development of Recombinant Influenza Vaccine Products and Manufacturing Capabilities for Pandemic Preparedness". FedBizOpps.gov. Retrieved 03May2014.
{{cite web}}: Check date values in:|accessdate=(help) - ^ "Adjuvant Pipeline". novavax.com. Retrieved 30Apr2014.
{{cite web}}: Check date values in:|accessdate=(help) - ^ Thomas, Dave. "Direct Analysis of Multicomponent Vaccine Adjuvants by HPLC with Charged Aerosol Detection" (PDF). thermoscientific.com. Retrieved 03May2014.
{{cite web}}: Check date values in:|accessdate=(help); line feed character in|title=at position 35 (help) - ^ Reimer, Jenny M.; Karlsson, Karin H.; Lövgren-Bengtsson, Karin; Magnusson, Sofia E.; Fuentes, Alexis; Stertman, Linda (23 Jul 2012). "Matrix-M™ Adjuvant Induces Local Recruitment, Activation and Maturation of Central Immune Cells in Absence of Antigen". PLOSone. doi:10.1371/journal.pone.0041451. Retrieved 03May2014.
{{cite journal}}: Check date values in:|accessdate=(help)CS1 maint: unflagged free DOI (link)